Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Lemahieu W et al. | Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. | 2005 | Am. J. Transplant. | pmid:15888045 |
Axelrod D et al. | Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients. | 2005 | Am. J. Transplant. | pmid:15888050 |
Reyes J et al. | Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). | 2005 | Am. J. Transplant. | pmid:15888051 |
Knoop C et al. | Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. | 2005 | Am. J. Transplant. | pmid:15888057 |
Djamali A et al. | Nox2 is a mediator of chronic CsA nephrotoxicity. | 2012 | Am. J. Transplant. | pmid:22568654 |
Cavadas PC et al. | Bilateral trans-humeral arm transplantation: result at 2 years. | 2011 | Am. J. Transplant. | pmid:21521475 |
Qazi Y et al. | Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data. | 2017 | Am. J. Transplant. | pmid:27775865 |
Egli A et al. | Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. | 2010 | Am. J. Transplant. | pmid:20840474 |
Zafrani L et al. | Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. | 2009 | Am. J. Transplant. | pmid:19538494 |
Touzot M et al. | Renal transplantation in HIV-infected patients: the Paris experience. | 2010 | Am. J. Transplant. | pmid:20840478 |
Krämer BK et al. | Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. | 2010 | Am. J. Transplant. | pmid:20840480 |
Wang Q et al. | Biodegradable microsphere-loaded tacrolimus enhanced the effect on mice islet allograft and reduced the adverse effect on insulin secretion. | 2004 | Am. J. Transplant. | pmid:15084166 |
Budde K et al. | Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. | 2014 | Am. J. Transplant. | pmid:25278376 |
O'Grady JG et al. | Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. | 2007 | Am. J. Transplant. | pmid:17109723 |
Böhmig GA et al. | Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. | 2007 | Am. J. Transplant. | pmid:17109725 |
Hanto DW et al. | Intraoperative administration of inhaled carbon monoxide reduces delayed graft function in kidney allografts in Swine. | 2010 | Am. J. Transplant. | pmid:20977633 |
Al-Massarani G et al. | Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. | 2008 | Am. J. Transplant. | pmid:18925903 |
Frassetto LA and Benet LZ | Pharmacogenomics and transplantation: where are we? | 2004 | Am. J. Transplant. | pmid:15147415 |
MacPhee IA et al. | The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. | 2004 | Am. J. Transplant. | pmid:15147425 |
Artz MA et al. | Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. | 2004 | Am. J. Transplant. | pmid:15147428 |
Schold JD | The burden of proof in the design of early phase clinical trials. | 2013 | Am. J. Transplant. | pmid:23802723 |
Chisholm-Burns MA et al. | Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. | 2013 | Am. J. Transplant. | pmid:23819827 |
Troppmann C et al. | Impact of portal venous pancreas graft drainage on kidney graft outcome in simultaneous pancreas-kidney recipients reported to UNOS. | 2004 | Am. J. Transplant. | pmid:15023146 |
Willicombe M et al. | Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. | 2011 | Am. J. Transplant. | pmid:21299828 |
Muthusamy AS et al. | Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. | 2008 | Am. J. Transplant. | pmid:18828772 |
Srinivas TR et al. | The noninferiority trial: don't don't do it. | 2010 | Am. J. Transplant. | pmid:21087412 |
Meier-Kriesche HU et al. | Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. | 2005 | Am. J. Transplant. | pmid:16095509 |
Senior PA et al. | Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. | 2005 | Am. J. Transplant. | pmid:16095517 |
RodrÃguez-Perálvarez M et al. | Tacrolimus exposure after liver transplantation in randomized controlled trials: too much for too long. | 2013 | Am. J. Transplant. | pmid:23621166 |
Vanhove T et al. | Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients. | 2017 | Am. J. Transplant. | pmid:28224698 |
Borrows R et al. | Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. | 2006 | Am. J. Transplant. | pmid:16433766 |
Shihab F et al. | Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus. | 2017 | Am. J. Transplant. | pmid:28141897 |
Kohnle M et al. | Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. | 2006 | Am. J. Transplant. | pmid:16433776 |
O'Connell PJ et al. | Multicenter Australian trial of islet transplantation: improving accessibility and outcomes. | 2013 | Am. J. Transplant. | pmid:23668890 |
Russ GR et al. | Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results. | 2013 | Am. J. Transplant. | pmid:23668931 |
RodrÃguez-Perálvarez M et al. | Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. | 2012 | Am. J. Transplant. | pmid:22703529 |
Budde K | How to use mTOR inhibitors? The search goes on. | 2011 | Am. J. Transplant. | pmid:21668636 |
Luan FL et al. | Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. | 2008 | Am. J. Transplant. | pmid:18786231 |
Chen G et al. | Anti-CD45RB monoclonal antibody prolongs renal allograft survival in cynomolgus monkeys. | 2007 | Am. J. Transplant. | pmid:17227555 |
Woywodt A et al. | Different preparations of tacrolimus and medication errors. | 2008 | Am. J. Transplant. | pmid:18786238 |
Servais A et al. | Interstitial fibrosis evolution on early sequential screening renal allograft biopsies using quantitative image analysis. | 2011 | Am. J. Transplant. | pmid:21672152 |
Senior PA et al. | Changes in renal function after clinical islet transplantation: four-year observational study. | 2007 | Am. J. Transplant. | pmid:17227560 |
Levi Z et al. | Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. | 2007 | Am. J. Transplant. | pmid:17229076 |
Ogawa T et al. | Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. | 2007 | Am. J. Transplant. | pmid:17229077 |
Miriuka SG et al. | mTOR inhibition induces endothelial progenitor cell death. | 2006 | Am. J. Transplant. | pmid:16796720 |
Ryan CM and Swanson DP | clinical research, innovative practice and IRB review: identifying and respecting boundaries. | 2007 | Am. J. Transplant. | pmid:17331113 |
Levy G et al. | REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. | 2014 | Am. J. Transplant. | pmid:24456049 |
Triñanes J et al. | Deciphering Tacrolimus-Induced Toxicity in Pancreatic β Cells. | 2017 | Am. J. Transplant. | pmid:28432716 |
Ciancio G et al. | Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. | 2012 | Am. J. Transplant. | pmid:22946986 |
Pallet N et al. | Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. | 2016 | Am. J. Transplant. | pmid:26990694 |